Illustrative image.

Letairis

Name: Letairis
Brand: GSK
Availability: InStock

Ambrisentan

Prescription required

$3825.00

5mg · 3 × 30 tablets · 3 months supply

BrandBranded medicine· By GSK

$1275.00 per month

Strength

How long a supply?

1 month$1275.00 a monthOne-off$1275.00

3 months$1275.00 a monthOne-off$3825.00

6 months$1275.00 a monthOne-off$7650.00

Supplied from Israel

Test mode: no payment is taken. View cart

Annual cost

$15300a year at this pack size

Prescription required

Upload your prescription after ordering, or send it to our pharmacy team. We dispense only against a valid prescription.

5mg

10mg

FDA boxed warningEmbryo-fetal toxicity

Letairis is contraindicated for use during pregnancy because it may cause major birth defects if used by pregnant patients, based on studies in animals.

Therefore, for females of reproductive potential, exclude pregnancy before the initiation of treatment with Letairis. Advise use of effective contraception before initiation, during treatment, and for one month after treatment with Letairis. When pregnancy is detected, discontinue Letairis as soon as possible.

Based on animal data Letairis may cause fetal harm if used during pregnancy.

Females of reproductive potential: Exclude pregnancy before the start of treatment. Use effective contraception prior to initiation of treatment, during treatment, and for one month after treatment with Letairis

Read this with the rest of the clinical information

About Letairis

Overview

Letairis contains ambrisentan, an endothelin receptor antagonist. It is used in adults with pulmonary arterial hypertension (PAH, WHO Group 1) to improve exercise ability and delay worsening of the condition. It can also be used with tadalafil to reduce the risks of disease progression and hospitalization for worsening PAH, and to improve exercise ability. It works by blocking endothelin-A receptors, which mediate blood vessel narrowing and cell growth in blood vessel walls.

What it treats

- Pulmonary arterial hypertension (PAH, WHO Group 1) in adults, to improve exercise ability and delay clinical worsening. - In combination with tadalafil for adult PAH, to reduce the risks of disease progression and hospitalization for worsening PAH, and to improve exercise ability.

Safety information

Side effects

Common side effects of Letairis include swelling, particularly in the arms or legs, nasal congestion, sinusitis and flushing. When taken with tadalafil, common side effects also include headache, cough, anemia, indigestion and bronchitis. Serious risks include fluid retention that may require treatment, fluid buildup in the lungs, harm to an unborn baby, decreased sperm count and reduced hemoglobin, which can cause anemia. Contact a doctor if swelling develops or worsens, and seek urgent medical attention for sudden breathing difficulty, which may indicate fluid buildup in the lungs. Contact your doctor promptly if you become pregnant. Hemoglobin can fall within the first few weeks of treatment. Blood tests are needed before starting Letairis, after one month and periodically during treatment.

FDA boxed warning

Embryo-fetal toxicity

Letairis is contraindicated for use during pregnancy because it may cause major birth defects if used by pregnant patients, based on studies in animals.

Based on animal data Letairis may cause fetal harm if used during pregnancy.

A boxed warning is the strongest warning the US Food and Drug Administration requires on a medicine label. Text is taken from the official label, with internal section references removed.

When to call your doctor

- You find out you are pregnant while taking Letairis; it may cause major birth defects. - You develop sudden difficulty breathing, which may indicate fluid in the lungs. - You develop new or worsening swelling in your feet, ankles or legs, which may indicate fluid retention.

If symptoms are severe or getting worse quickly, seek emergency care rather than waiting.

Before taking this medicine

Do not take Letairis (ambrisentan) if you are pregnant or have idiopathic pulmonary fibrosis. It is not recommended for people with moderate or severe liver impairment. If you are breastfeeding, a choice must be made between taking Letairis and breastfeeding. Letairis can cause fluid retention that may need treatment. If acute fluid buildup in the lungs develops when treatment begins, the prescriber should consider underlying pulmonary veno-occlusive disease and stop treatment if necessary. Decreased sperm counts have been observed in people taking endothelin receptor antagonists. Hemoglobin levels may fall within the first few weeks of treatment. Hemoglobin should be checked before starting treatment, after one month and periodically thereafter.

Interactions

Cyclosporine can approximately double the amount of ambrisentan in the body. Tell your doctor if you take cyclosporine, as your ambrisentan dose will need to be limited.

Using Letairis

Dosing

Dosing is set by your prescriber. Each health care professional may prescribe medication differently according to a patient's medical history and condition, so follow the directions on your prescription label and speak to your doctor or pharmacist before changing anything.

Storage

Store below 25°C in a dry place, in the original pack, away from direct light and moisture. Do not keep it in a bathroom. Keep all medicines out of the sight and reach of children.

Clinical information on this page is summarised from the US FDA label LETAIRIS (AMBRISENTAN) TABLET, FILM COATED [GILEAD SCIENCES, INC.] (DailyMed, retrieved 19 September 2026).

Reviews

No reviews yet. Mail Order Drugs opened recently, and we publish reviews only from verified customers of this site, so this space stays empty until real ones arrive.